Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043784 · ClinicalTrials.gov registry record · Phase 3
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
A Phase 3 study of Myocardial Infarction and Myocardial Ischemia, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,000
- Enrollment target
- 1
- Study location
NCT00043784 is a Phase 3 study of Myocardial Infarction and Myocardial Ischemia that has completed, run by Sanofi. The registered enrollment target is 8,000 participants, above the 4,557-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (76% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00043784, a Phase 3 study of Myocardial Infarction and Myocardial Ischemia, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.
Conditions Studied
Interventions
- DRUG enoxaparin
Study Locations (1)
North Carolina
- Duke Clinical Research Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2001-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043784
The ClinicalTrials.gov registry entry for NCT00043784 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 4,557-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (76% higher). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Myocardial Infarction appearing as the primary indexed condition, and to 1 intervention - of which enoxaparin is the first listed.
NCT00043784 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00043784 about?
NCT00043784 is a clinical study titled "SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes". Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.
What is the current status of trial NCT00043784?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,000 participants. The study started on 2001-08.
What conditions does trial NCT00043784 study?
This clinical trial studies the following conditions: Myocardial Infarction, Myocardial Ischemia, Unstable Angina.
What interventions are being tested in trial NCT00043784?
The interventions under investigation include: enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00043784?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043784 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging
COMPLETED · Phase 3
-
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
COMPLETED · Phase 3
-
Occluded Artery Trial (OAT)
COMPLETED · Phase 3
-
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
COMPLETED · Phase 3
-
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
COMPLETED · Phase 3
-
Myocardial Ischemia and Transfusion Pilot
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.